Case studies showing clinical signs and management of cutaneous toxicity of the MEK1/2 inhibitor AZD6244 (ARRY-142886) in patients with solid tumours

Ingrid M. E. Desar Department of Medical Oncology, Radboud University Nijmegen Medical Centre, Nijmegen, The NetherlandsCorrespondence[email protected]

H. Jorn Bovenschen Department of Dermatology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands

Anja J. N. H. Timmer-Bonte Department of Medical Oncology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands; Department of Pulmonary Diseases, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands

Mireille V. Cantarini AstraZeneca, Alderley Park, UK

Winette T. A. van der Graaf Department of Medical Oncology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands

Michelle M. van Rossum Department of Dermatology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands

Carla M. L. van Herpen Department of Medical Oncology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands

show all

Click to increase image sizeClick to decrease image size

Acknowledgements

We thank Dr Sally Humphries, from MediTech Media, who provided editing assistance funded by AstraZen-eca. The patients were participating in a phase I trial sponsored by AstraZeneca. Declaration of interest: Dr. M. Cantarini is an employee of AstraZeneca. All other authors do not declare any conflicts of interest.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Case studies showing clinical signs and management of cutaneous toxicity of the MEK1/2 inhibitor AZD6244 (ARRY-142886) in patients with solid tumours

Information for

Open access

Opportunities

Help and information

Case studies showing clinical signs and management of cutaneous toxicity of the MEK1/2 inhibitor AZD6244 (ARRY-142886) in patients with solid tumours

Acknowledgements

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature